Abstract
Inhibition of the proinflammatory cytokine TNF-α has been shown to be an effective strategy for treating inflammatory dermatoses. Etanercept competitively inhibits the interaction of TNF, interrupting the proinflammatory cytokine cascade and preventing TNF mediated cellular responses. The success of etanercept in a wide range of dermatologic conditions especially in psoriasis gives a new hope in dermatological therapy field. This article reviews the pharmacokinetic properties, safety profile, administration route and efficacy in different dermatological conditions of etanercept.
Keywords: tumour necrosis factor aplha, Cytokines, TNF inhibitors, Psoriasis, Inflammatory Diseases
Related Journals
Related Books
Molecular Aspects of Hepatocellular Carcinoma
Current Diagnosis of Infant Tuberculosis Infection
Physiopathogenesis of Hematological Cancer
The Role of New Technologies in Medical Microbiological Research and Diagnosis
The Role of Saliva Cortisol Measurement in Health and Disease
Current Topics on Fetal 3D/4D Ultrasound
Molecular Oncology: Principles and Recent Advances
Multi Drug Resistance: A Global Concern
Awake Thoracic Surgery
Preventive Female Sex Factors Against The Development of Chronic Liver Disease
7